Platelet α-granule secretion and its modification by SC-57101A, a GPIIb/IIIa antagonist

Biochemical Pharmacology

Volumn 63, Issue 10, 2002, Pages 1911-1918

  Ogawa, Taketoshi ^a   Sugidachi, Atsuhiro ^a   Otsuguro, Ken Ichi ^a   Isobe, Takashi ^a   Asai, Fumitoshi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Granule; GPIIb IIIa; Orbofiban; Platelets; SC 57101A; Secretion

Indexed keywords

3 [[[1 [4 (AMINOIMINOMETHYL)PHENYL] 2 OXO 3 PYRROLIDINYL]AMINO]CARBONYL]PROPANOATE; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; COLLAGEN; FIBRINOGEN RECEPTOR ANTAGONIST; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E1; SC 57101A; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG ELIMINATION; DRUG INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION;

ASPIRIN; BETA-ALANINE; BETA-THROMBOGLOBULIN; BLOOD PLATELETS; DRUG INTERACTIONS; HUMANS; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE-PHOSPHATASE; UREA;

EID: 0037094462     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)00976-0     Document Type: Article

References (29)

1. Platelet inhibitor agents in cardiovascular disease: An update
2. Platelet activation in unstable coronary disease
3. Biochemical evidence of platelet activation in patients with persistent unstable angina
4. The biology of platelet-derived growth factor
5. Salivary beta-thromboglobulin: A possible marker for deep vein thrombosis following elective hip surgery
6. GMP-140: A receptor for neutrophils and monocytes on activated platelets and endothelium
7. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction
8. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty
9. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial
10. Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs
11. Changes in glycoprotein IIb/IIIa complex during platelet activation
12. The aggregation of blood platelets
13. GPIIb-IIIa: The responsive integrin
14. Tyrosine phosphorylation of pp125FAK in platelets requires coordinated signaling through integrin and agonist receptors
15. Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation
16. 2 production
17. The anti-aggregating peptide KRDS impairs α-granule release, whereas RGDS does not
18. 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728
19. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia
20. Paradoxical inhibition of fibrinogen binding and potentiation of α-granule release by specific types of inhibitors of glycoprotein IIb-IIIa
21. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters
22. Comparative study of antiplatelet drugs in vitro: Distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses
23. Flow cytometric analysis of platelet activation by different collagen types present in the vessel wall
24. 2 synthesis
25. 2 formation on close contact of human platelets in media with a low concentration of ionized calcium
26. Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition site(s) on platelet glycoprotein IIb·IIIa complex inhibits receptor function
27. 2
28. 2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway
29. 2-induced platelet aggregation